Institute of Life Science, College of Medicine, Swansea University, Singleton Park, Swansea SA2 8PP, Wales, UK.
Mutat Res. 2012 Jun 14;745(1-2):104-11. doi: 10.1016/j.mrgentox.2011.09.013. Epub 2011 Sep 28.
There is a pressing requirement to define a hazard identification and risk management strategy for nanomaterials due to the rapid growth in the nanotechnology industry and their promise of life-style revolutions through the development of wide-ranging nano-containing consumer products. Consequently, a battery of well defined and appropriate in vitro assays to assess a number of genotoxicity endpoints is required to minimise extensive and costly in vivo testing. However, the validity of the established protocols in current OECD recognised genotoxicity assays for nanomaterials is currently being questioned. In this report, we therefore consider the in vitro OECD genotoxicity test battery including the Ames, micronucleus and HPRT forward mutation assays, and their potential role in the safety assessment of nanomaterial induced DNA damage in vitro.
由于纳米技术产业的快速发展及其通过开发广泛的含纳米消费品带来生活方式革命的前景，因此迫切需要定义纳米材料的危害识别和风险管理策略。因此，需要一系列定义明确且适当的体外检测方法来评估多种遗传毒性终点，以尽量减少广泛而昂贵的体内测试。然而，目前正在质疑当前经合组织认可的纳米材料遗传毒性检测中既定方案的有效性。因此，在本报告中，我们考虑了体外 OECD 遗传毒性检测试剂盒，包括艾姆斯试验、微核试验和 HPRT 正向突变试验，以及它们在纳米材料诱导的体外 DNA 损伤的安全性评估中的潜在作用。
